Condition
Botulinum Toxin, Type A
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 4 (1)
Trial Status
Completed2
Enrolling By Invitation1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06677216Enrolling By Invitation
Botulinum Toxin in the Management of Temporo-mandibular Related Myalgia: a Prospective Study
NCT06556030Phase 4Not Yet RecruitingPrimary
A Multicentre, Randomised, Single-blind, Controlled Protocol to Evaluate the Efficacy of Early Administration of Botulinum Toxin for Primary Midline Closure in Patients With Open Abdomen.
NCT05324839Early Phase 1CompletedPrimary
A Study of Botulinum Toxin Type A Treatment of Wrinkles in Asian
NCT04131348Not ApplicableCompletedPrimary
Botulinum Toxin to Avoid Component Separation in Midline Large Hernias
Showing all 4 trials